Clinical Trial Update: Sodium/Glucose Cotransporter-2 Inhibitors (SGLT2i) Therapy in Duchenne Cardiomyopathy [Phase 1]

View source ↗

Summary

Phase 1 clinical trial assessing SGLT2 inhibitors as therapy for Duchenne cardiomyopathy in Duchenne muscular dystrophy; recruitment not yet started.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Duchenne Cardiomyopathy
• Duchenne Muscular Dystrophy

Drugs mentioned

• Canagliflozin (canagliflozin)
• Dapagliflozin (dapagliflozin)
• Empagliflozin (empagliflozin)

Snippet

Sponsor: Larry W. Markham | Conditions: Duchenne Muscular Dystrophy (DMD) | Phase 1 | Status: NOT_YET_RECRUITING